Amylyx Pharmaceuticals, INC. (AMLX) — 10-Q Filings

10-Q Filings (6)

• Amylyx Shifts Focus Amidst Zero Revenue, Bolsters Cash by $147M — Nov 6, 2025 Risk: high
  Amylyx Pharmaceuticals, Inc. (AMLX) reported a significant net loss of $111.7 million for the nine months ended September 30, 2025, a substantial improvement fr
• Amylyx's Net Loss Widens to $100.2M Despite 25% Revenue Growth — Aug 7, 2025 Risk: high
  Amylyx Pharmaceuticals, Inc. reported a net loss of $100.2 million for the six months ended June 30, 2025, a significant increase from the $75.8 million net los
• Amylyx Pharmaceuticals Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and operations, including de
• Amylyx Pharmaceuticals Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its quarterly report for the period ending September 30, 2024. The company's financial statements and disclosures are present
• Amylyx Pharmaceuticals Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and business updates. Key financial
• Amylyx Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. (AMLX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Amylyx Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX